These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 36134930)

  • 1. Harnessing Protein Corona for Biomimetic Nanomedicine Design.
    Chen Z; Chen X; Huang J; Wang J; Wang Z
    Biomimetics (Basel); 2022 Sep; 7(3):. PubMed ID: 36134930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
    Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
    Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine.
    Cai R; Chen C
    Adv Mater; 2019 Nov; 31(45):e1805740. PubMed ID: 30589115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of protein corona on the biological behavior of targeting nanomedicines.
    Farshbaf M; Valizadeh H; Panahi Y; Fatahi Y; Chen M; Zarebkohan A; Gao H
    Int J Pharm; 2022 Feb; 614():121458. PubMed ID: 35017025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein corona: challenges and opportunities for targeted delivery of nanomedicines.
    Jiang Z; Chu Y; Zhan C
    Expert Opin Drug Deliv; 2022 Jul; 19(7):833-846. PubMed ID: 35738018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How protein coronas determine the fate of engineered nanoparticles in biological environment.
    Capjak I; Goreta SŠ; Jurašin DD; Vrček IV
    Arh Hig Rada Toksikol; 2017 Dec; 68(4):245-253. PubMed ID: 29337683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bypassing Protein Corona Issue on Active Targeting: Zwitterionic Coatings Dictate Specific Interactions of Targeting Moieties and Cell Receptors.
    Safavi-Sohi R; Maghari S; Raoufi M; Jalali SA; Hajipour MJ; Ghassempour A; Mahmoudi M
    ACS Appl Mater Interfaces; 2016 Sep; 8(35):22808-18. PubMed ID: 27526263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into colloidal nanoparticle-protein corona interactions for nanomedicine applications.
    Martínez-Negro M; González-Rubio G; Aicart E; Landfester K; Guerrero-Martínez A; Junquera E
    Adv Colloid Interface Sci; 2021 Mar; 289():102366. PubMed ID: 33540289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Protein Corona on the Biological Identity of Nanomedicine: Understanding the Fate of Nanomaterials in the Biological Milieu.
    Akhter MH; Khalilullah H; Gupta M; Alfaleh MA; Alhakamy NA; Riadi Y; Md S
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering a Nano/Biointerface for Cell and Organ-Selective Drug Delivery.
    Song D; Xu Q
    Langmuir; 2022 Aug; 38(30):9092-9098. PubMed ID: 35852946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Fate of Nanoparticles In Vivo and the Strategy of Designing Stealth Nanoparticle for Drug Delivery.
    Bao J; Zhang Q; Duan T; Hu R; Tang J
    Curr Drug Targets; 2021; 22(8):922-946. PubMed ID: 33461465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disentangling Biomolecular Corona Interactions With Cell Receptors and Implications for Targeting of Nanomedicines.
    Aliyandi A; Zuhorn IS; Salvati A
    Front Bioeng Biotechnol; 2020; 8():599454. PubMed ID: 33363128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biomolecule corona mediates pulmonary delivery of nanomedicine.
    Subramaniam S; Joyce P; Prestidge CA
    Eur J Pharm Biopharm; 2024 Sep; 202():114420. PubMed ID: 39038525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link?
    Jain P; Pawar RS; Pandey RS; Madan J; Pawar S; Lakshmi PK; Sudheesh MS
    Biotechnol Adv; 2017 Nov; 35(7):889-904. PubMed ID: 28844973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of protein corona on the behavior and targeting capability of nanoparticle-based delivery system.
    Xiao W; Gao H
    Int J Pharm; 2018 Dec; 552(1-2):328-339. PubMed ID: 30308270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein corona: Dr. Jekyll and Mr. Hyde of nanomedicine.
    Fasoli E
    Biotechnol Appl Biochem; 2021 Dec; 68(6):1139-1152. PubMed ID: 33007792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between nanoparticles-protein corona complex and cells and its toxic effect on cells.
    Liu N; Tang M; Ding J
    Chemosphere; 2020 Apr; 245():125624. PubMed ID: 31864050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of biomimetic nanoparticles for tumor-targeted drug delivery.
    Li B; Wang F; Gui L; He Q; Yao Y; Chen H
    Nanomedicine (Lond); 2018 Aug; 13(16):2099-2118. PubMed ID: 30226404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling the in Vivo Protein Corona of Circulating Leukocyte-like Carriers.
    Corbo C; Molinaro R; Taraballi F; Toledano Furman NE; Hartman KA; Sherman MB; De Rosa E; Kirui DK; Salvatore F; Tasciotti E
    ACS Nano; 2017 Mar; 11(3):3262-3273. PubMed ID: 28264157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research progress and application opportunities of nanoparticle-protein corona complexes.
    Huang W; Xiao G; Zhang Y; Min W
    Biomed Pharmacother; 2021 Jul; 139():111541. PubMed ID: 33848776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.